MA47450A - Sulfinylpyridines et leur utilisation dans le traitement du cancer - Google Patents

Sulfinylpyridines et leur utilisation dans le traitement du cancer

Info

Publication number
MA47450A
MA47450A MA047450A MA47450A MA47450A MA 47450 A MA47450 A MA 47450A MA 047450 A MA047450 A MA 047450A MA 47450 A MA47450 A MA 47450A MA 47450 A MA47450 A MA 47450A
Authority
MA
Morocco
Prior art keywords
sulfinylpyridines
cancer
treatment
Prior art date
Application number
MA047450A
Other languages
English (en)
Inventor
Kjell Andersson
Owe Orwar
Benjamin Pelcman
William Stafford
Original Assignee
Oblique Therapeutics Ab
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Oblique Therapeutics Ab filed Critical Oblique Therapeutics Ab
Publication of MA47450A publication Critical patent/MA47450A/fr

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D213/00—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members
    • C07D213/02—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members
    • C07D213/04—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom
    • C07D213/60—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D213/72—Nitrogen atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D213/00—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members
    • C07D213/02—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members
    • C07D213/04—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom
    • C07D213/60—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D213/62—Oxygen or sulfur atoms
    • C07D213/70—Sulfur atoms
    • C07D213/71—Sulfur atoms to which a second hetero atom is attached
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Epidemiology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Pyridine Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
MA047450A 2017-02-07 2018-02-07 Sulfinylpyridines et leur utilisation dans le traitement du cancer MA47450A (fr)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US201762455645P 2017-02-07 2017-02-07

Publications (1)

Publication Number Publication Date
MA47450A true MA47450A (fr) 2019-12-18

Family

ID=61226605

Family Applications (1)

Application Number Title Priority Date Filing Date
MA047450A MA47450A (fr) 2017-02-07 2018-02-07 Sulfinylpyridines et leur utilisation dans le traitement du cancer

Country Status (12)

Country Link
US (2) US11208384B2 (fr)
EP (1) EP3580204A1 (fr)
JP (1) JP2020507624A (fr)
KR (1) KR20190115011A (fr)
CN (1) CN110382465A (fr)
AU (1) AU2018218518B2 (fr)
BR (1) BR112019016258A2 (fr)
CA (1) CA3051644A1 (fr)
MA (1) MA47450A (fr)
MX (1) MX2019009356A (fr)
RU (1) RU2019127896A (fr)
WO (1) WO2018146468A1 (fr)

Families Citing this family (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB201514021D0 (en) 2015-08-07 2015-09-23 Arner Elias Set Jeno Novel Pyridines and their use in the treatment of cancer
KR20190115012A (ko) 2017-02-07 2019-10-10 오블리크 세러퓨틱스 에이비 헤테로사이클릴설포닐-치환된 피리딘 및 암의 치료에서 이의 용도
KR20190115013A (ko) 2017-02-07 2019-10-10 오블리크 세러퓨틱스 에이비 헤테로아릴설포닐-치환된 피리딘 및 암의 치료에서 이의 용도
EP3580203A1 (fr) 2017-02-07 2019-12-18 Oblique Therapeutics AB Pyridines à substitution hydrocarbylsulfonyle et leur utilisation dans le traitement du cancer
MX2019009356A (es) * 2017-02-07 2019-09-19 Oblique Therapeutics Ab Sulfinilpiridinas y su uso en el tratamiento del cancer.
CA3091085A1 (fr) * 2018-02-12 2019-08-15 Cinda Pharma Ab Inhibiteurs de la thioredoxine reductase a utiliser dans le traitement du cancer

Family Cites Families (46)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP0031173B1 (fr) 1979-12-19 1983-09-14 Duphar International Research B.V Nitrothiophènes, procédé pour leur préparation, ainsi que compositions fongicides et/ou bactéricides les contenant
AU543161B2 (en) 1980-03-07 1985-04-04 E.I. Du Pont De Nemours And Company Pyrimidine or s.triazine derivatives
US4456469A (en) 1980-03-07 1984-06-26 E. I. Du Pont De Nemours And Company Pyridyl sulfone herbicides
US4791127A (en) 1985-10-07 1988-12-13 Nippon Kayaku Kabushiki Kaisha Alkanesulfonate derivatives and their use as insecticides, acaricides or nematicides
DE3812177A1 (de) * 1988-04-13 1989-10-26 Bayer Ag 2-phenylsulfinyl-nitro-pyridine, verfahren zu ihrer herstellung und ihre verwendung
US5945425A (en) 1994-04-29 1999-08-31 G.D. Searle & Co. Method of using (H+ /K+)ATPase inhibitors as antiviral agents
DE19531148A1 (de) 1995-08-24 1997-02-27 Basf Ag Fungizide Pyridin-2-yl-Derivate
EP0850223A1 (fr) 1995-08-24 1998-07-01 Basf Aktiengesellschaft Composes n-heterocycliques, produits intermediaires utilises pour les preparer, agents les contenant et utilisation pour lutter contre des champignons nuisibles
US6191280B1 (en) 1997-05-30 2001-02-20 Basf Aktiengesellschaft Method for producing substituted thiopyridines
US6284923B1 (en) 1997-08-22 2001-09-04 Tularik Inc Substituted benzene compounds as antiproliferative and cholesterol lowering action
WO1999018096A1 (fr) 1997-10-02 1999-04-15 Merck & Co., Inc. Inhibiteurs de la prenyl-proteine transferase
US6297239B1 (en) 1997-10-08 2001-10-02 Merck & Co., Inc. Inhibitors of prenyl-protein transferase
US6191170B1 (en) 1998-01-13 2001-02-20 Tularik Inc. Benzenesulfonamides and benzamides as therapeutic agents
ATE236136T1 (de) 1998-01-16 2003-04-15 Hoffmann La Roche Benzosulfonderivate
ES2254385T3 (es) 2000-02-29 2006-06-16 Millennium Pharmaceuticals, Inc. Benzamidas e inhibidores relacionados del factor xa.
US20030187026A1 (en) 2001-12-13 2003-10-02 Qun Li Kinase inhibitors
WO2003068744A1 (fr) 2002-02-18 2003-08-21 Ishihara Sangyo Kaisha, Ltd. Derives de la pyridine ou leurs sels, et inhibiteurs de production de citokine renfermant ces derives
US20030236287A1 (en) 2002-05-03 2003-12-25 Piotrowski David W. Positive allosteric modulators of the nicotinic acetylcholine receptor
US7037902B2 (en) 2002-07-03 2006-05-02 Receptron, Inc. Affinity small molecules for the EPO receptor
WO2005007621A2 (fr) 2003-05-30 2005-01-27 Rigel Pharmaceuticals, Inc. Inhibiteurs de ligase d'ubiquitine
HRP20090093T3 (en) 2004-06-04 2009-03-31 Arena Pharmaceuticals Inc. Substituted aryl and heteroaryl derivatives as modulators of metabolism and the prophylaxis and treatment of disorders related thereto
US20060019967A1 (en) * 2004-07-21 2006-01-26 Su-Ying Wu SARS CoV main protease inhibitors
GB0426313D0 (en) 2004-12-01 2005-01-05 Merck Sharp & Dohme Therapeutic agents
WO2006083692A2 (fr) 2005-01-28 2006-08-10 Mount Sinai Schoool Of Medicine Procédés d'identification de modulateurs de bromodomaines
GB0504828D0 (en) 2005-03-09 2005-04-13 Merck Sharp & Dohme Therapeutic agents
EP1976495A2 (fr) 2006-01-06 2008-10-08 Aarhus Universitet Composes agissant sur le transporteur de la serotonine
CA2647338A1 (fr) 2006-04-28 2007-11-08 Avexa Limited Inhibiteurs de l'integrase-3
EP2061472A4 (fr) * 2006-05-22 2010-12-22 Thioredoxin Systems Ab Inhibiteurs de thioredoxine reductase bacterienne et procédés d'utilisation afférents
US20100190777A1 (en) 2007-07-17 2010-07-29 Plexxikon Inc. Compounds and methods for kinase modulation, and indications therefor
CN101723932B (zh) 2008-10-31 2013-11-20 北京以岭生物工程技术有限公司 硝基吡啶乙烯亚胺化合物、其药物组合物及其制备方法和用途
US9421211B2 (en) * 2009-05-28 2016-08-23 President And Fellows Of Harvard College N,N′-diarylurea compounds and N,N′-diarylthiourea compounds as inhibitors of translation initiation
NZ598262A (en) 2009-08-17 2014-05-30 Sloan Kettering Inst Cancer Heat shock protein binding compounds, compositions, and methods for making and using same
WO2011099502A1 (fr) 2010-02-10 2011-08-18 公立大学法人横浜市立大学 Utilisation d'un composé se liant à msin3b qui se lie, de façon spécifique, au facteur silenceur de la spécification neuronale nrsf
CN102206172B (zh) 2010-03-30 2015-02-25 中国医学科学院医药生物技术研究所 一组取代双芳基化合物及其制备方法和抗病毒应用
WO2012025638A1 (fr) 2010-08-27 2012-03-01 Universität des Saarlandes Inhibiteurs sélectifs de la 17-bêta-hydroxystéroïde déshydrogénase de type 1
AU2013216885B2 (en) 2012-02-10 2017-08-03 The Board Of Regents Of The University Of Texas System Modulators of exchange proteins directly activated by cAMP (EPACs)
US8946418B1 (en) 2013-07-10 2015-02-03 Boehringer Ingelheim International Gmbh Chiral nitrogen-phosphorus ligands and their use for asymmetric hydrogenation of alkenes
CN104672214B (zh) 2013-12-03 2019-04-12 上海翰森生物医药科技有限公司 具有alk抑制活性的化合物及其制备与用途
CN105503827B (zh) 2014-10-11 2019-09-24 上海翰森生物医药科技有限公司 Egfr抑制剂及其制备方法和用途
CN104987324B (zh) 2015-06-04 2018-05-04 湖北生物医药产业技术研究院有限公司 作为alk抑制剂的嘧啶衍生物
CN105085483B (zh) 2015-06-04 2019-01-01 湖北生物医药产业技术研究院有限公司 激酶抑制剂及其应用
GB201514021D0 (en) 2015-08-07 2015-09-23 Arner Elias Set Jeno Novel Pyridines and their use in the treatment of cancer
KR20190115013A (ko) 2017-02-07 2019-10-10 오블리크 세러퓨틱스 에이비 헤테로아릴설포닐-치환된 피리딘 및 암의 치료에서 이의 용도
MX2019009356A (es) * 2017-02-07 2019-09-19 Oblique Therapeutics Ab Sulfinilpiridinas y su uso en el tratamiento del cancer.
KR20190115012A (ko) 2017-02-07 2019-10-10 오블리크 세러퓨틱스 에이비 헤테로사이클릴설포닐-치환된 피리딘 및 암의 치료에서 이의 용도
EP3580203A1 (fr) 2017-02-07 2019-12-18 Oblique Therapeutics AB Pyridines à substitution hydrocarbylsulfonyle et leur utilisation dans le traitement du cancer

Also Published As

Publication number Publication date
RU2019127896A (ru) 2021-03-09
BR112019016258A2 (pt) 2020-04-07
KR20190115011A (ko) 2019-10-10
WO2018146468A1 (fr) 2018-08-16
MX2019009356A (es) 2019-09-19
US20200024233A1 (en) 2020-01-23
AU2018218518B2 (en) 2022-03-17
CA3051644A1 (fr) 2018-08-16
US20220177430A1 (en) 2022-06-09
JP2020507624A (ja) 2020-03-12
CN110382465A (zh) 2019-10-25
EP3580204A1 (fr) 2019-12-18
RU2019127896A3 (fr) 2021-05-18
US11208384B2 (en) 2021-12-28
AU2018218518A1 (en) 2019-08-15

Similar Documents

Publication Publication Date Title
MA45122A (fr) Inhibiteurs hétérocycliques de cbp/ep300 et leur utilisation dans le traitement du cancer
MA52886A (fr) Composés de purinone et leur utilisation dans le traitement du cancer
MA43163A (fr) Polypeptides à domaine extracellulaire cd80 et leur utilisation dans le traitement du cancer
EP3684353A4 (fr) Formulations topiques de cannabinoïdes et leur utilisation dans le traitement de la douleur
MA39960A (fr) Composés imidazo[4,5c]quinoline-2-one et leur utilisation dans le traitement du cancer
HUE054548T2 (hu) Amino-triazolopiridin vegyületek és azok alkalmazása rák kezelésében
SI3240554T1 (sl) Blautia stercosis in wexlerae za uporabo v zdravljenju vnetnih in avtoimunskih bolezni
PL3303632T3 (pl) Terapeutyczne i diagnostyczne sposoby stosowane w nowotworze
EP3673947A4 (fr) Cathéter et ensemble cathéter
EP3796920A4 (fr) Compositions d'arnt/pré-miarn et leur utilisation dans le traitement du cancer
MA42915A (fr) Pyridines et leur utilisation dans le traitement du cancer
MA47452A (fr) Pyridines à substitution hétérocyclylsulfonyle et leur utilisation dans le traitement du cancer
EP2969010A4 (fr) Utilisation de levocetirizine et de montelukast dans le traitement des maladies auto-immunes
MA47451A (fr) Pyridines à substitution hétéroarylsulfonyle et leur utilisation dans le traitement du cancer
MA47458A (fr) Pyridines à substitution hydrocarbylsulfonyle et leur utilisation dans le traitement du cancer
PL3229794T3 (pl) Kombinacja farmaceutyczna obejmująca ponesimod i jej zastosowanie w leczeniu stwardnienia rozsianego
MA44762A (fr) Sémaglutide utilisé dans le traitement de maladies cardiovasculaires
EP2969002A4 (fr) Utilisation de levocetirizine et montelukast dans le traitement de blessure traumatique
EP3678692A4 (fr) Stratification du génotype dans le traitement et la prévention du diabète
EP3848022C0 (fr) Agent thérapeutique pour utilisation dans le traitement d'infections
EP3258964A4 (fr) Détection et traitement de tumeurs malignes dans le snc
EP3349742A4 (fr) Utilisation de niclosamide dans le traitement de cellules déficientes en p53
EP3397063A4 (fr) Utilisation de microbulles et de nanobulles dans le traitement de liquide
MA45046A (fr) Irinotécan nanoliposomal utilisé dans le traitement du cancer bronchique à petites cellules
EP3363461A4 (fr) Anticorps anti-cd43 et leur utilisation pour le traitement du cancer